A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer
Clinical trial NCT04993430 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04993430
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-26
- Primary completion
- 2026-12-30
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.